Partnership to use multi-target approach for novel cancer therapies discovery

UK-based biopharmaceutical company PhoreMost and US quantum computing drug design business Polaris Quantum Biotech, are combining their technologies for the search and development of next generation oncology therapies derived from targets previously considered to be undruggable.

Under the terms of the agreement the POLARISqb Tachyon™ platform will be used to scan billions of molecules from a large chemical space, seeking novel molecular drugs based on information obtained from PhoreMost’s SITESEEKER® phenotypic screening platform. It is expected that the increased power of the quantum computer will drastically shorten the drug discovery process, through the ability to perform combinatorial optimisations in minutes that would take classical supercomputers months or even years to complete.

“This collaboration is a significant milestone for POLARISqb,” said Dr. Shahar Keinan, POLARISqb CEO. “Quantum Computing technology is coming of age, allowing us to revolutionise drug discovery timelines and budgets, while improving the overall profile of the designed drugs. The experience and speed of PhoreMost’s technology is a great match to POLARISqb and we are excited to work together." 

Dr Chris Torrance, CEO, PhoreMost, commented: “This partnership represents the ultimate ambition for any collaboration between biology and technology, where the full diversity of newly identified druggable disease targets generated by biological PROTEINi shape-libraries can now be married to the most logical and rapid method of finding small-molecule drugs to them. This best-in-class intersection of biotech and AI is going to be an exciting and transformative milestone for the entire pharmaceutical industry.”

More information online